Business · 1 sources covering this

Eli Lilly's Foundayo Tops Oral Semaglutide On Key Measures In Type 2 Diabetes Trial

Over 52 weeks, the Achieve-3 study compared two doses of Foundayo with approved oral semaglutide doses in 1,698 people with type 2 diabetes who were not adequately controlled on metformin.

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

NDTVCenter·2h ago
Eli Lilly's Foundayo Tops Oral Semaglutide On Key Measures In Type 2 Diabetes Trial
Over 52 weeks, the Achieve-3 study compared two doses of Foundayo with approved oral semaglutide doses in 1,698 people with type 2 diabetes who were not adequately controlled on metformin.
Read at NDTV →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/9a091d142f7ffa5804c41c786f823a9b483ce865"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Eli Lilly's Foundayo Tops Oral Semaglutide On Key Measures In Type 2 Diabetes Trial"></iframe>

Eli Lilly's Foundayo Tops Oral Semaglutide On Key Measures In Type 2 Diabetes Trial

How 1 sources are covering this

Eli Lilly's Foundayo Tops Oral Semaglutide On Key Measures In Type 2 Diabetes Trial

More from Business

US-Iran War News Live Updates: Donald Trump 'Close To' Ordering Strikes On Iran; Calls It A 'Failed Nation'

FIFA World Cup 2026 Group A Preview: Mexico Favourites In Tricky Pool With South Korea, Czechia

Carlyle Eyes India IPO For Healthcare RCM Provider After Recent Acquisition

Stock markets retreat from day’s high; end flat

Reader

Trust & legal

Across the network